GlassScriptPhysician profile
Ekta K Perera
NPI 1083025902
$74,665.65
in general payments reported to CMS, 2019-2025
29 companies · $63K in 2025
The $63K reported for 2025 was more than what 97% of Allergy & Immunology (Internal Medicine) providers received nationally (typical 2025 total: $681).
See the full distribution for Allergy & Immunology (Internal Medicine)
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $1,236 · 2020: $467 · 2021: $105 · 2022: $141 · 2023: $403 · 2024: $8,924 · 2025: $63K.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program: $47K · Consulting Fee: $11K · Food and Beverage: $7,942 · Travel and Lodging: $6,243 · Education: $274.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program | $46,885.00 |
| Consulting Fee | $11,374.00 |
| Food and Beverage | $7,942.39 |
| Travel and Lodging | $6,242.62 |
| Education | $273.72 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Astrazeneca Pharmaceuticals LP | $58,327.94 | 2020-2025 | Fasenra, Tezspire, Airsupra |
| Genzyme Corporation | $11,596.67 | 2024-2025 | |
| Glaxosmithkline, LLC. | $1,006.90 | 2019-2025 | Nucala, Trelegy Ellipta |
| Regeneron Healthcare Solutions, INC. | $897.98 | 2021-2025 | Dupixent |
| Takeda Pharmaceuticals U.S.A., INC. | $417.52 | 2024-2025 | Cuvitru |
| Csl Behring | $323.26 | 2019-2025 | Hizentra |
| Pharming Healthcare, INC. | $314.38 | 2020-2025 | Ruconest |
| Novartis Pharmaceuticals Corporation | $247.86 | 2022-2025 | |
| Grifols USA, LLC | $242.57 | 2023-2025 | Xembify |
| Octapharma USA, INC. | $154.69 | 2019 | |
| Janssen Pharmaceuticals, INC | $150.00 | 2023 | Xarelto |
| Teva Pharmaceuticals USA, INC. | $135.44 | 2019 | |
| Genentech, INC. | $128.25 | 2024 | Xolair |
| Genentech USA, INC. | $123.43 | 2019 | |
| Shire North American Group INC | $120.73 | 2019 |
Show all 29 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Actelion Pharmaceuticals US, INC. | $92.03 | 2024 | Uptravi, Opsumit |
| Sanofi-Aventis U.S. LLC | $76.99 | 2024 | |
| Pfizer INC. | $46.01 | 2025 | |
| Janssen Biotech, INC. | $36.94 | 2022 | |
| Blueprint Medicines Corporation | $34.73 | 2025 | Ayvakit |
| Ars Pharmaceuticals Operations, INC. | $33.32 | 2025 | Neffy |
| Greer Laboratories, INC. | $31.43 | 2023 | Oralair |
| Lilly USA, LLC | $24.46 | 2025 | Ebglyss |
| Paratek Pharmaceuticals, INC. | $20.83 | 2025 | Xhance |
| Harmony Biosciences LLC | $19.65 | 2024 | |
| Jubilant Hollisterstier LLC | $19.50 | 2023 | |
| Phadia US INC. | $15.24 | 2025 | Immunocap |
| Insmed, INC. | $13.57 | 2025 | Brinsupri |
| Gc Biopharma USA, INC. | $13.33 | 2024 | Alyglo |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Ekta Perera listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.